SG11201809469QA - [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones - Google Patents

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones

Info

Publication number
SG11201809469QA
SG11201809469QA SG11201809469QA SG11201809469QA SG11201809469QA SG 11201809469Q A SG11201809469Q A SG 11201809469QA SG 11201809469Q A SG11201809469Q A SG 11201809469QA SG 11201809469Q A SG11201809469Q A SG 11201809469QA SG 11201809469Q A SG11201809469Q A SG 11201809469QA
Authority
SG
Singapore
Prior art keywords
berlin
international
disorders
compounds
strasse
Prior art date
Application number
SG11201809469QA
Inventor
Marcus Koppitz
Holger Siebeneicher
Holger Steuber
Laak Antonius Ter
Reinhard Nubbemeyer
Antje Rottmann
Horst Irlbacher
Benjamin Bader
Michaele Peters
Andrea Wagenfeld
Ildiko Terebesi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201809469QA publication Critical patent/SG11201809469QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 01 010 1101 OH 0101111111011011# Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/202817 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, CO7D 487/08 (2006.01) A61P 29/00 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 31/498 (2006.01) A61P 35/00 (2006.01) A61P 15/00 (2006.01) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (21) International Application Number: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, PCT/EP2017/062359 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 23 May 2017 (23.05.2017) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (25) Filing Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English (30) Priority Data: Declarations under Rule 4.17: 16171538.8 26 May 2016 (26.05.2016) EP — as to applicant's entitlement to apply for and be granted a 16178891.4 11 July 2016 (11.07.2016) EP patent (Rule 4.1700) (71) Applicant: BAYER PHARMA AKTIENGESEL- Published: LSCHAFT [DE/DE]; Milllerstr. 178, 13353 Berlin (DE). — with international search report (Art. 21(3)) (72) Inventors: KOPPITZ, Marcus; ElsenbruchstraBe 34A, 13467 Berlin (DE). SIEBENEICHER, Holger; Krupp- strasse 18, 10557 Berlin (DE). STEUBER, Holger; Han- noversche Strasse 19a, 10115 Berlin (DE). TER LAAK, Antonius; Hedwigstrasse 11, 12159 Berlin (DE). NUBBE- MEYER, Reinhard; Moorweg 96, 13509 Berlin (DE). ROTTMANN, Antje; Schneehompfad 11A, 13089 Berlin (DE). IRLBACHER, Horst; Winsstrasse 47, 10405 Berlin (DE). BADER, Benjamin; Hillmannstrasse 14, 13467 Berlin (DE). PETERS, Michaele; Heinrich-Roller Strasse 1, 10405 Berlin (DE). WAGENFELD, Andrea; Weddin- genweg 64, 12205 Berlin (DE). TEREBESI, Ildiko; Re- ichensteiner Weg 5, 14195 Berlin (DE). Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein NRW (DE). (74) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (81) Title: [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]0CT-3-YL] (1H-1,2,3-TRIAZOL-4-YL)METHANONES (54) 1-1 (57) : The present invention covers [8-(phenylsulfony1)-3,8- diazabicyclo[3.2.1]oct-3-y1R1H-1,2,3-triazol-4-yl)methanone compounds of general for- 1-1 mula (I) in which R 1 , R, R , R 2 3 4 and R 5 are as defined herein, methods of preparing said GC e , ' ei 110 R 4 compounds, intermediate compounds useful for preparing said compounds, pharmaceuti- cal compositions and combinations comprising said compounds and the use of said com- N—S ` , 0 pounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of IN I I disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic N 0 ,1 N ii \ (I) disorders, or inflammatory disorders as a sole agent or in combination with other active 0 ei 'N ingredients. H C
SG11201809469QA 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones SG11201809469QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171538 2016-05-26
EP16178891 2016-07-11
PCT/EP2017/062359 WO2017202817A1 (en) 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones

Publications (1)

Publication Number Publication Date
SG11201809469QA true SG11201809469QA (en) 2018-11-29

Family

ID=58765840

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809469QA SG11201809469QA (en) 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones

Country Status (25)

Country Link
US (1) US10167293B2 (en)
EP (1) EP3464288B1 (en)
JP (1) JP6918020B2 (en)
KR (2) KR102509150B1 (en)
CN (4) CN109311898B (en)
AU (1) AU2017269871B2 (en)
BR (1) BR112018074381B1 (en)
CA (1) CA3025420A1 (en)
CY (1) CY1123955T1 (en)
DK (1) DK3464288T3 (en)
ES (1) ES2856964T3 (en)
HR (1) HRP20210424T1 (en)
HU (1) HUE053438T2 (en)
IL (1) IL262982B (en)
LT (1) LT3464288T (en)
MX (1) MX2018014541A (en)
PE (1) PE20190204A1 (en)
PL (1) PL3464288T3 (en)
RS (1) RS61520B1 (en)
SA (1) SA518400501B1 (en)
SG (1) SG11201809469QA (en)
SI (1) SI3464288T1 (en)
TW (1) TWI738782B (en)
UY (1) UY37262A (en)
WO (1) WO2017202817A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825478A (en) * 2016-12-19 2018-07-16 德商拜耳製藥公司 [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
JP7178075B2 (en) * 2018-03-22 2022-11-25 株式会社ユニバーサルコーポレーション AKR1C3 selective inhibitor and use thereof
CN110183455B (en) * 2019-06-18 2021-04-20 中国医科大学 Azabicyclo [3.2.1] octan-3-one compounds, preparation method and application thereof
WO2021000862A1 (en) 2019-07-01 2021-01-07 深圳艾欣达伟医药科技有限公司 Akr1c3 inhibitor and medical use
UY38806A (en) * 2019-08-01 2021-02-26 Novartis Ag AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2707999A (en) 1998-03-11 1999-09-27 Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
EP1990335A4 (en) * 2006-03-02 2009-11-11 Astellas Pharma Inc 17 beta hsd type 5 inhibitor
US20070259879A1 (en) 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
EP2004619A1 (en) 2006-03-23 2008-12-24 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
CN101495113A (en) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 IL-8 receptor antagonists
WO2008008912A1 (en) * 2006-07-14 2008-01-17 Genelabs Technologies, Inc. Antiviral agents
EP2056828A4 (en) 2006-08-21 2010-06-23 Merck Sharp & Dohme Sulfonylated piperazines as cannabinoid-1 receptor modulators
AU2008244648A1 (en) * 2007-02-16 2008-11-06 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
JP2011504878A (en) * 2007-11-26 2011-02-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing imidazoazepinone compound
JP5578498B2 (en) * 2009-11-10 2014-08-27 国立大学法人 千葉大学 Anticancer agent kit and anticancer agent effect enhancer
DE102011083725A1 (en) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
AP2014008179A0 (en) 2012-07-10 2014-12-31 Bayer Pharma AG 3-Substituted estra-1,3,5(10), 16-tetraene derivativess, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
EA201590356A1 (en) * 2012-08-16 2015-07-30 Байер Фарма Акциенгезельшафт 2,3-benzodiazepines
WO2014039820A1 (en) 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
AU2014220800A1 (en) 2013-02-21 2015-08-27 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1 C3)
JP2015020966A (en) * 2013-07-18 2015-02-02 岐阜市 Akr1c3 inhibitor
US20170260226A1 (en) * 2014-09-11 2017-09-14 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors

Also Published As

Publication number Publication date
BR112018074381B1 (en) 2024-01-23
CN109311898B (en) 2022-04-12
UY37262A (en) 2018-01-02
LT3464288T (en) 2021-01-25
KR20190009318A (en) 2019-01-28
CN114699413A (en) 2022-07-05
MX2018014541A (en) 2019-03-28
RS61520B1 (en) 2021-03-31
DK3464288T3 (en) 2021-03-08
WO2017202817A9 (en) 2018-12-06
PL3464288T3 (en) 2021-07-12
TW201742868A (en) 2017-12-16
IL262982B (en) 2022-03-01
CY1123955T1 (en) 2022-05-27
IL262982A (en) 2018-12-31
AU2017269871A1 (en) 2018-11-15
TWI738782B (en) 2021-09-11
SI3464288T1 (en) 2021-03-31
CN114702503A (en) 2022-07-05
HRP20210424T1 (en) 2021-04-30
CA3025420A1 (en) 2017-11-30
PE20190204A1 (en) 2019-02-05
US20180319807A2 (en) 2018-11-08
US20170342082A1 (en) 2017-11-30
AU2017269871B2 (en) 2021-05-20
US10167293B2 (en) 2019-01-01
JP6918020B2 (en) 2021-08-11
ES2856964T3 (en) 2021-09-28
SA518400501B1 (en) 2022-01-16
CN114702503B (en) 2023-12-22
KR102509150B1 (en) 2023-03-10
CN109311898A (en) 2019-02-05
WO2017202817A1 (en) 2017-11-30
KR20220035507A (en) 2022-03-22
KR102373202B1 (en) 2022-03-10
CN114699414A (en) 2022-07-05
BR112018074381A2 (en) 2019-03-06
EP3464288A1 (en) 2019-04-10
EP3464288B1 (en) 2020-12-23
JP2019516763A (en) 2019-06-20
HUE053438T2 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
SG11201810366WA (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
SG11201809469QA (en) [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201808214TA (en) Pyrazolopyrimidine derivatives
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201901141WA (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG11201808108XA (en) Synthesis of indazoles
SG11201903059SA (en) New anthelmintic quinoline-3-carboxamide derivatives
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407837WA (en) Beta-hairpin peptidomimetics
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808686VA (en) Synthesis of indazoles
SG11201805001UA (en) Method of treating influenza a
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201906557UA (en) Novel stable formulation for fxia antibodies
SG11201909243TA (en) New bicyclic pyrazole derivatives
SG11201805755SA (en) Methods of administering hepcidin
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201408509PA (en) Racecadotril lipid compositions